It is also important to note that no tumour BRCA1/2 test has been validated to distinguish between germline and somatic pathogenic variants, so all patients with a tumour BRCA1/2 pathogenic variant, irrespective of the tumour test used, should undergo germline testing. The gene discussed is BRCA1; the disease is neoplasm.